{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:24:42Z","timestamp":1759335882131,"version":"3.41.2"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.leukres.2025.107717","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:26:54Z","timestamp":1748892414000},"page":"107717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4921-5809","authenticated-orcid":false,"given":"Brian A.","family":"Jonas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha C.","family":"Fisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1853-3752","authenticated-orcid":false,"given":"Peter T.","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary J.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-4428","authenticated-orcid":false,"given":"Dimitrios","family":"Tzachanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Bejar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Wieduwilt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Tuscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-5321","authenticated-orcid":false,"given":"Lloyd","family":"Damon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1179-5879","authenticated-orcid":false,"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2025.107717_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2014.11.001","article-title":"MDS prognostic scoring systems \u2013 past, present, and future","volume":"28","author":"Jonas","year":"2015","journal-title":"Best. Pr. Res Clin. Haematol. [Internet]"},{"issue":"13","key":"10.1016\/j.leukres.2025.107717_bib2","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"De Witte","year":"2017","journal-title":"Blood [Internet]"},{"issue":"4","key":"10.1016\/j.leukres.2025.107717_bib3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamaoncol.2019.5140","article-title":"Comparison of patient age groups in transplantation for myelodysplastic syndrome: the medicare coverage with evidence development study","volume":"6","author":"Atallah","year":"2020","journal-title":"JAMA Oncol. [Internet]"},{"issue":"30","key":"10.1016\/j.leukres.2025.107717_bib4","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"11","key":"10.1016\/j.leukres.2025.107717_bib5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/ajh.25950","article-title":"Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management","volume":"95","author":"Garcia-Manero","year":"2020","journal-title":"Am. J. Hematol. [Internet]"},{"issue":"12","key":"10.1016\/j.leukres.2025.107717_bib6","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood [Internet]"},{"issue":"7","key":"10.1016\/j.leukres.2025.107717_bib7","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid. [Internet]"},{"issue":"10","key":"10.1016\/j.leukres.2025.107717_bib8","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"4","key":"10.1016\/j.leukres.2025.107717_bib9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"24","key":"10.1016\/j.leukres.2025.107717_bib10","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"8","key":"10.1016\/j.leukres.2025.107717_bib11","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","article-title":"Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells","volume":"98","author":"Guzman","year":"2001","journal-title":"Blood [Internet]"},{"issue":"7","key":"10.1016\/j.leukres.2025.107717_bib12","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/1541-7786.MCR-12-0607","article-title":"Epigenetic control of NF-\u03baB-dependent FAS gene transcription during progression of myelodysplastic syndromes","volume":"11","author":"Ettou","year":"2013","journal-title":"Mol. Cancer Res [Internet]"},{"issue":"6","key":"10.1016\/j.leukres.2025.107717_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3324\/haematol.12261","article-title":"The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma","volume":"93","author":"Khong","year":"2008","journal-title":"Haematol. [Internet]"},{"issue":"8","key":"10.1016\/j.leukres.2025.107717_bib14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood-2013-06-511154","article-title":"Identification of Bruton\u2019s tyrosine kinase as a therapeutic target in acute myeloid leukemia","volume":"123","author":"Rushworth","year":"2014","journal-title":"Blood [Internet]"},{"issue":"20","key":"10.1016\/j.leukres.2025.107717_bib15","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.18632\/oncotarget.2479","article-title":"Ibrutinib inhibits SDF1\/CXCR4 mediated migration in AML","volume":"5","author":"Zaitseva","year":"2014","journal-title":"Oncotarget [Internet]"},{"issue":"5","key":"10.1016\/j.leukres.2025.107717_bib16","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2352-3026(15)00046-0","article-title":"Activity of Bruton\u2019s tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells","volume":"2","author":"Rushworth","year":"2015","journal-title":"Lancet Haematol. [Internet]"},{"key":"10.1016\/j.leukres.2025.107717_bib17","article-title":"Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia","volume":"5","author":"Pillinger","year":"2015","journal-title":"Sci. Rep. [Internet]"},{"issue":"12","key":"10.1016\/j.leukres.2025.107717_bib18","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood-2014-06-585216","article-title":"FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation","volume":"125","author":"Oellerich","year":"2015","journal-title":"Blood [Internet]"},{"issue":"5","key":"10.1016\/j.leukres.2025.107717_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.leukres.2014.03.001","article-title":"NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients","volume":"38","author":"Kuroda","year":"2014","journal-title":"Leuk. Res [Internet]"},{"issue":"6","key":"10.1016\/j.leukres.2025.107717_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.prp.2014.02.006","article-title":"Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis","volume":"210","author":"Kunze","year":"2014","journal-title":"Pathol. Res Pr. [Internet]"},{"issue":"10","key":"10.1016\/j.leukres.2025.107717_bib21","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood-2011-12-399683","article-title":"Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations","volume":"120","author":"Will","year":"2012","journal-title":"Blood [Internet]"},{"issue":"12","key":"10.1016\/j.leukres.2025.107717_bib22","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nri953","article-title":"Lymphoid malignancies: the dark side of B-cell differentiation","volume":"2","author":"Shaffer","year":"2002","journal-title":"Nat. Rev. Immunol. [Internet]"},{"issue":"15","key":"10.1016\/j.leukres.2025.107717_bib23","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood [Internet]"},{"issue":"5","key":"10.1016\/j.leukres.2025.107717_bib24","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2141.2011.08683.x","article-title":"Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy","volume":"153","author":"Aggarwal","year":"2011","journal-title":"Br. J. Haematol. [Internet]"},{"issue":"5","key":"10.1016\/j.leukres.2025.107717_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.leukres.2013.01.019","article-title":"IL10 inversely correlates with the percentage of CD8+ cells in MDS patients","volume":"37","author":"Lopes","year":"2013","journal-title":"Leuk. Res [Internet]"},{"issue":"3","key":"10.1016\/j.leukres.2025.107717_bib26","first-page":"510","article-title":"Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+\u2009regulatory T cells in myelodysplastic syndromes (MDS)","volume":"23","author":"Kotsianidis","year":"2009","journal-title":"Leuk. [Internet]"},{"issue":"3","key":"10.1016\/j.leukres.2025.107717_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0609.2008.01182.x","article-title":"Clinical significance of regulatory T cells in patients with myelodysplastic syndrome","volume":"82","author":"Hamdi","year":"2009","journal-title":"Eur. J. Haematol. [Internet]"},{"issue":"3","key":"10.1016\/j.leukres.2025.107717_bib28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3324\/haematol.2020.268136","article-title":"Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes","volume":"107","author":"van Leeuwen-Kerkhoff","year":"2022","journal-title":"Haematol. [Internet]"},{"issue":"2","key":"10.1016\/j.leukres.2025.107717_bib29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood [Internet]"},{"issue":"5","key":"10.1016\/j.leukres.2025.107717_bib30","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood [Internet]"},{"issue":"2","key":"10.1016\/j.leukres.2025.107717_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br. J. Haematol."},{"issue":"03","key":"10.1016\/j.leukres.2025.107717_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: a 2D graphics environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Comput. Sci. Eng."},{"issue":"40","key":"10.1016\/j.leukres.2025.107717_bib33","first-page":"1317","article-title":"Davidson-pilon c. lifelines: survival analysis in python software \u2022 review \u2022 repository \u2022 archive","volume":"4","year":"2019","journal-title":"J. Open Source Softw. [Internet]"},{"key":"10.1016\/j.leukres.2025.107717_bib34","article-title":"Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy","volume":"122","author":"Fisch","year":"2022","journal-title":"Leuk. Res [Internet]"},{"key":"10.1016\/j.leukres.2025.107717_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.05.008","article-title":"Clinical experience with ibrutinib alone or in combination with either cytarabine or azacitidine in patients with acute myeloid leukemia","author":"Cortes","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"18","key":"10.1016\/j.leukres.2025.107717_bib36","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/bloodadvances.2020002846","article-title":"Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS","volume":"4","author":"Huls","year":"2020","journal-title":"Blood Adv. [Internet]"},{"issue":"3","key":"10.1016\/j.leukres.2025.107717_bib37","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2024, nccn clinical practice guidelines in oncology","volume":"22","author":"Wierda","year":"2024","journal-title":"J. Natl. Compr. Canc Netw. [Internet]"},{"issue":"3","key":"10.1016\/j.leukres.2025.107717_bib38","article-title":"TP53 mutations in acute leukemias and myelodysplastic syndromes: insights and treatment updates","volume":"44","author":"Santini","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book [Internet]"},{"issue":"14","key":"10.1016\/j.leukres.2025.107717_bib39","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (apr-246) and azacitidine in tp53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"15","key":"10.1016\/j.leukres.2025.107717_bib40","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"10","key":"10.1016\/j.leukres.2025.107717_bib41","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol. [Internet]"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:15:14Z","timestamp":1753157714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":41,"alternative-id":["S0145212625000773"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107717","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107717"}}